• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer

Video

Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.

Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
4 experts are featured in this series.
1 expert is featured in this series.
Anna Mueller, MD, Mount Sinai
Marc Humbert, MD, PhD
John Ostrominski, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.